Mechanical Circulatory Support Devices Market Report 2025

The mechanical circulatory support devices market size has grown rapidly in recent years. It will grow from $3.14 billion in 2024 to $3.47 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth during the historic period can be attributed to the increasing prevalence of end-stage heart failure, higher post-surgery survival rates, expansion of bridge-to-transplant procedures, greater awareness among cardiologists, and a rising aging global population.

The mechanical circulatory support devices market size is expected to see rapid growth in the next few years. It will grow to $5.08 billion in 2029 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period is expected to be driven by the rising incidence of cardiovascular diseases, increased adoption of destination therapy, growing global healthcare expenditure, expanding clinical trials for next-generation devices, favorable regulatory support, and a shortage of heart donors for transplantation. Key trends during this period include the development of fully implantable ventricular assist device (VAD) systems, integration of smart sensors into devices, adoption of artificial intelligence for monitoring, advancements in magnetically levitated pumps, and innovations in biocompatible polymers and coatings.

The increasing prevalence of heart failure is expected to drive the growth of the mechanical circulatory support devices market in the coming years. Heart failure is a chronic condition in which the heart cannot pump sufficient blood to meet the body’s needs. This condition is becoming more common due to the aging population, as older adults are more susceptible to cardiovascular diseases and related complications. Mechanical circulatory support devices assist the heart by improving blood circulation, easing the workload on a weakened heart, and enhancing overall cardiac function. For example, in September 2024, the Heart Failure Society of America (HFSA), a US-based non-profit organization, reported that heart failure currently affects 6.7 million Americans over the age of 20. This number is projected to rise to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. This increasing prevalence of heart failure is thus driving demand for mechanical circulatory support devices.

Companies in the mechanical circulatory support devices market are developing advanced technologies, such as magnetically levitated rotor (MAGLEV) technology, to provide more efficient and reliable devices that improve heart function and patient survival. MAGLEV technology uses magnetic fields to suspend and rotate a rotor without physical contact, reducing friction and wear for smoother and longer-lasting device performance. For instance, in July 2024, BiVACOR Inc., a US-based clinical-stage medical device company, performed the first-in-human implantation of its Total Artificial Heart (TAH). This device is designed to fully replace both ventricles in patients with severe biventricular or univentricular heart failure who are not eligible for conventional left ventricular assist devices, offering a crucial bridge-to-transplant solution and the potential to enhance survival and quality of life for patients facing limited treatment options due to donor heart scarcity.

In December 2022, Johnson & Johnson Services Inc., a US-based healthcare company, acquired Abiomed Inc. for \$16.6 billion. This acquisition aims to expand Johnson & Johnson’s MedTech portfolio and accelerate growth in the cardiovascular market by integrating Abiomed’s innovative heart recovery solutions. Abiomed Inc., based in the US, develops and manufactures mechanical circulatory support (MCS) devices.

Major players in the mechanical circulatory support devices market are Johnson & Johnson, Abbott Laboratories, Medtronic Plc, Fresenius Medical Care AG & Co. KGaA, Boston Scientific Corporation, Terumo Corporation, Teleflex Incorporated, Getinge AB, LivaNova PLC, Supira Medical Inc., BrioHealth Solutions Inc., Magenta Medical Ltd., CorWave SA, Jarvik Heart Inc., Carmat SAS, Procyrion Inc., BiVACOR Inc., CardioBridge GmbH, Evaheart Inc., and ReliantHeart Inc.

North America was the largest region in the mechanical circulatory support devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mechanical circulatory support devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mechanical circulatory support devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Mechanical circulatory support devices are sophisticated medical technologies designed to assist or replace the heart’s pumping function in patients with severe heart failure or other cardiac conditions. These devices ensure adequate blood flow and oxygen delivery to vital organs when the heart is unable to perform effectively. They are employed as life-saving interventions to stabilize patients, enhance quality of life, and, in some cases, act as a bridge to heart transplantation or recovery.

The primary types of mechanical circulatory support devices include the intra-aortic balloon pump, ventricular assist device, total artificial heart, and extracorporeal membrane oxygenation. An intra-aortic balloon pump assists the heart by inflating and deflating a balloon within the aorta, improving blood flow and reducing cardiac workload. The main technologies used are pulsatile flow devices and non-pulsatile flow devices. These devices find applications in cardiac surgery, heart failure management, myocardial infarction, and cardiogenic shock, and are utilized by a range of end users including hospitals, ambulatory surgical centers, specialty clinics, and others.

The mechanical circulatory support devices market research report is one of a series of new reports that provides mechanical circulatory support devices market statistics, including the mechanical circulatory support devices industry global market size, regional shares, competitors with the mechanical circulatory support devices market share, detailed mechanical circulatory support devices market segments, market trends, and opportunities, and any further data you may need to thrive in the mechanical circulatory support devices industry. This mechanical circulatory support devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mechanical circulatory support devices market consists of revenues earned by entities by providing services such as technical support, patient monitoring, device calibration, repair, clinical consultation, performance testing, and emergency assistance. The market value includes the value of related goods sold by the service provider or included within the service offering. The mechanical circulatory support devices market also includes sales of intra-aortic balloon pump, ventricular assist device, total artificial heart, extracorporeal membrane oxygenation, pulsatile flow device, non-pulsatile flow device, and implantable device. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.